Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1143-1149

  Michelakis, Evangelos D ^a,c   Weir, E Kenneth ^b   Nelson, Daniel P ^b   Reeve, Helen L ^b   Tolarova, Simona ^b   Archer, Stephen L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ANGIOTENSIN; ANOREXIGENIC AGENT; DEXFENFLURAMINE; FLUOXETINE; KETANSERIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM ION; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEART OUTPUT; HEMODYNAMIC PARAMETERS; MALE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

4-AMINOPYRIDINE; ANIMALS; ARTERIES; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNELS; DEXFENFLURAMINE; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; ION CHANNEL GATING; KETANSERIN; MALE; MEMBRANE POTENTIALS; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032755920     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simoneau G and Begaud B (1996) Appetite-suppresant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609-616.
2. American Heart Association (1998) American Heart Association urges caution on a new diet drug. Circulation 97:B3.
3. Archer S, Djaballah K, Humbert M, Weir E, Fartoukh M, Simonneau G and Dinh-Xuan A (1998) Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine. Am J Resp Crit Care Med 158:1061-1067.
4. Archer SL, Huang JMC, Reeve HL, Hampl V, Tolarova S, Michelakis ED and Weir EK (1996) Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ Res 78:431-442.
5. Awouters F (1985) The pharmacology of ketanserin, the first selective serotonin S2 antagonist. Drug Dev Res 6:263-300.
6. Celada P, Martin F and Artigas F (1994) Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 55:1237-1243.
7. Cheymol G, Weissenburger J, Poirier JM and Gellee C (1995) The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 39:684-687.
8. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD and Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588.
9. Coupar IM, Hedges A, Metcalfe HL and Turner P (1969) Action of fenfluramine on isolated human smooth muscle. Lancet 1:925-926.
10. Dahm P, Thorne J, Zoucas E, Martensson L, Myhre E and Blomquist S (1997) Differential effects of nitric oxide synthase modulation on porcine systemic and pulmonary circulation in vivo. Crit Care Med 25:280-285.
11. Desta B, Schultz D, Ravel D, Laudignon N, Vanhoute PM and Boulanger CM (1996) Acute and chronic effects of dexfenfluramine on the porcine coronary artery. J Pharmacol Exp Ther 279:1077-1085.
12. Evrard P, Allaz AF (1990) Myocardial infarction associated with the use of dexfenfluramine. Br Med J 301:345.
13. Forte P, Copland M, Smith LM, Milne E, Sutherland J and Benjamin N (1997) Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-842.
14. Frishman WH, Huberfeld S, Okin S, Wang Y, Kumar A and Shareef B (1995) Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35:541-572.
15. Gibson EL, Kennedy AJ and Curzon G (1993) D-Fenfluramine- and n-norfenfluramine-induced hypophagia: Differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur J Pharmacol 242:83-90.
16. 2+/EDRF signaling are due to generation of superoxide anions. Diabetes 45:1386-1395.
17. Hampl V, Archer SL, Nelson DP and Weir EK (1993) Chronic EDRF inhibition and hypoxia: Effects on the pulmonary circulation and systemic blood pressure. J Appl Physiol 75:1748-1757.
18. Heal D, Cheetham S, Prow M, Martin K and Buckett W (1998) A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 125:301-308.
19. Hossain M and Campbell DB (1975) Fenfluramine and methylcellulosein in the treatment of obesity: The relationship between plasma drug concentrations and the therapeutic efficacy. Postgrad Med 51 (Suppl 1):178-182.
20. Hoyer D, Clarke D, Fozard J, Hartig P, Martin G, Mylecharane E, Saxena P and Humphrey P (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203.
21. + channels by dexfenfluramine (Redux). J Pharmacol Exp Ther 287:480-486.
22. Innes JA, Watson ML, Ford MJ, Munro JF, Stoddart ME and Campbell DB (1977) Plasma fenfluramine levels, weight loss and side effects. Br Med J 2:1322-1325.
23. Khan M, Herzog C, St Peter J, Hartley G, Madlon-Kay R, Dick C, Asinger R and Vessey J (1988) The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 339:713-718.
24. Kirchner KA, Scanlon PH, Dzielak DJ and Hester RL (1993) Endothelium-derived relaxing factor responses in DOCA-salt hypertensive rats. Am J Physiol 265: R568-R572.
25. + channels in the cerebral microcirculation of genetically hypertensive rats: Evidence for their protection against cerebral vasospasm. Circ Res 82:729-737.
26. Mabadeje AF (1974) Fenfluramine-induced hypertension. West Afr J Pharmacol Drug Res 2:P54.
27. Marinella M and Berrettoni B (1997) Digital necrosis associated with dexfenfluramine. N Engl J Med 337:1776-1777.
28. Martens J and Gelband C (1998) Ion channels in vascular smooth muscle: Alterations in essential hypertension. Proc Soc Exp Biol Med 218:192-203.
29. McNeely W and Goa K (1998) Sibutramine. A review of its contribution to the management of obesity. Drugs 56:1093-1124.
30. McTavish D and Heel R (1992) Dexfenfluramine: A review of its pharmacologic properties and therapeutic potential in obesity. Drugs 43:713-733.
31. Mlczoch J, Weir E, Reeves J and Grover R (1979) Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation of the pig. Basic Res Cardiol 74:313-320.
32. Nelin LD and Dawson CA (1993) The effect of N omega-nitro-L-arginine methylester on hypoxic vasoconstriction in the neonatal pig lung. Pediatr Res 34:349-353.
33. Nelson M and Quayle J (1995) Physiological roles and properties of potassium channels in arterial smooth muscle cells. Am J Physiol 37:C799-C822.
34. Patel A, Lazdunski M and Honore E (1997) Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K channel in oxygen-sensitive pulmonary artery myocytes. EMBO J 16:6615-6625.
35. Pietrusko R, Strunkard A, Brownwll K and Campbell DB (1982) Plasma fenfluramine levels, weight loss and side effects: A failure to find a relationship. Int J Obesity 6:567-571.
36. Redmon B, Raatz S and Bantle J (1997) Letter to the editor. N Engl J Med 337:1773-1774.
37. Schembre D and Boynton K (1997) Letter to the editor. N Engl J Med 336:510-511.
38. Schwitter J, Agosti R, Ott P, Kalman A and Waespe W (1992) Small infarctions of cochlear, retinal and encephalic tissue in young women. Stroke 23:903-907.
39. Takimoto K, Li D, Hershman K, Li P, Jackson E and Levitan E (1997) Decreased expression of Kv4.2 and novel Kv4.3 K+ channel subunit mRNAs in ventricles of renovascular hypertensive rats. Circ Res 81:533-539.
40. Van Gaal L, Wauters M and De Leeuw I (1998) Anti-obesity drugs: What does sibutramine offer? An analysis of its potential contribution to obesity treatment. Exp Clin Endocrinol Diabetes 106 (Suppl 2):35-40.
41. Weir EK, Reeve HL, Huang J, Michelakis E, Nelson DP, Hampl V and Archer SL (1996) Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-2220.
42. Yuan X, Aldinger A, Juhaszova M, Wang J, Conte J, Gaine S, Orens J and Rubin L (1998) Dysfunctional voltage-gated potassium channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98:1400-1406.